Enrollment completed in Phase 2 ENVISION clinical trial
September 20, 2022
The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
AMD
Study: Comparing biosimilar of ranibizumab and Lucentis in efficacy and safety for wet AMD
September 20, 2022
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
European Commission approves faricimab for nAMD, DME
September 19, 2022
Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.
Suspension of regular ophthalmic treatment for AMD during COVID-19 Pandemic resulted in increased visual loss
September 16, 2022
Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration (AMD) during the COVID-19 lockdown who were followed over time.
Adverum Biotechnologies announces first subject dosed with Ixo-vec in the Phase 2 LUNA trial for treatment of wet AMD
September 16, 2022
LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.
Dark adaptation for vision diagnostic platform unveiled
September 15, 2022
Heru debuts dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up.
Ashvattha Therapeutics enrolls first patient in Phase 2 study of D-4517.2 for treatment of wet AMD, DME
September 07, 2022
The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
Outlook Therapeutics re-submits BLA for ONS-5010
August 31, 2022
ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.
Trinity team’s new gene therapy shows promise for treating eye condition affecting millions across the globe
August 26, 2022
Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that is the first of its kind to directly target mitochondrial function in cells that are malfunctioning in AMD.
EyePoint Pharmaceuticals announces first patient dosed in Phase 2 DAVIO 2 clinical trial
August 03, 2022
According to the company, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).